
Hardware, Software, Meet Wetware: A Computer With 800,000 Human Neurons
The Cortical Labs CL1 biological computer with human brain cells.
The world's first 'code-deployable' biological computer is now for sale. The Cortical Labs CL1 costs $35,000 and has 800,000 human brain cells living and growing in a nutrient solution on a silicon chip. Computer scientists can deploy computer code directly to these neurons, which have been integrated into a 'biOS' or Biological Intelligence Operating System with what the company says is a mixture of hard silicon and soft tissue.
The goal, according to the companies' founder? Smarter AI that drops some of the A and adds more of the I. Maybe, eventually, smarter brains than the ones we currently walk around with.
'The only machine or the only thing that we know of that actually has true intelligence is the brain,' founder and CEO Hon Weng Chong told me when I interviewed him five years ago, while he was still using mice neurons. 'So we said, let's start with the basic building structure, the building blocks being neurons, and let's build our way up and maybe we'll get there along the way.'
Our human brains have neurons connected together in hierarchies, and from that emerges intelligence and consciousness, he adds. This approach is similar to neuromorphic computing architectures, which attempt to mimic biological brains with silicon-based hardware, but of course different in that neuromorphic chips do not typically use actual living brain cells.
Cortical Labs, based in Australia, says scientists can solve today's most difficult problems with their biological computers, which they say are self-programming and infinitely flexible.
A key difference between biological computers and silicon-based chips, of course, is that biological computers last even less time. The neurons that ship with your CL1 will live for 'up to six months,' at which point you'll likely have to invest in a refresh or refurbishment which provides new neurons for continued compute. And yes, biological computers need food and water and nutrients, all of which are supplied onboard via a life-support system the keeps them at optimum temperature. Plus, it filters out waste byproducts of living human cells: the kind of work kidneys might do in a full living organism.
A Cortical Labs chip under a high-powered electron microscope. You can see tight connections between ... More neurons and the silicon substrate, the company says.
In some ways the CL1 is more like a space ship than a computer, because it's a self-contained life support system that requires few external inputs. A key difference: the need for external power.
From the outside, though, you treat the CL1 as a typical computer.
You can plug in USB devices, cameras, even actuators if you want your CL1 to control a physical system. (Which, frankly, human neurons are typically pretty good at.) And there's a touchscreen so you can see system status or view live data.
Five years ago, Cortical Lab's then-CTO Andy Kitchen told me they were deploying systems with tens of thousands of neurons to hundreds of thousands of neurons, but that their roadmap included 'scaling that up to millions of neurons." Now Cortical Labs sees their biological computers growing to hundreds of millions of cells, and with different technologies, billion or trillion-cell levels.
However, there's not a direct one-to-one equivalent with neuromorphic neurons in a silicon-based system, he added. Biological neurons are much more powerful, he says.
Interestingly, communicating with physical human neurons in a biological computer is vastly different than writing computer code to an artificial computer.
'The premier way would be to describe your task somehow, probably through some sort of very high-level language, and then we would turn that into a stimulus sequence which would shape biological behavior to fit your specification,' Kitchen told me.
Part of the difference is how to encode and communicate the problem, and part of the difference is that the CL1 neurons, like the ones in your brain right now, have some plasticity: they can essentially reprogram themselves for different tasks. Essentially, the neurons learn how to solve your problem, just like you learn how to do new things.
You won't likely see CL1 systems in general use anytime soon: currently, the targeted customers are in medical fields like drug discovery and disease modeling, says IEEE Spectrum. There's the added value that scientists can perform experiments on a little synthetic brain as well.
If all of this seems on the edge of creepy, or even right over, that's likely because it is. CL1 says they don't do any animal testing, although they did start with mouse neurons, and they say that the human brain cells in their biological computers are lab-grown. But clearly the first human neurons came from somewhere.
Cortical Labs says customers have to get 'ethical approval' to general cell lines, and require buyers to have proper facilities to maintain the biological chips. What exactly that means, however, is unclear.
Soon we may see physical system in the world, like humanoid robots, with partially organic components to their brains.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Finland's AIATELLA secures funds for AI cardiovascular imaging solutions
Finnish startup AIATELLA has raised €2m ($2.27m) in financing to develop and scale its cardiovascular imaging technology powered by AI. The investment will support the company in conducting clinical trials and further developing its ultrasound-based preventative screening tool, which can identify and quantify carotid artery narrowing within minutes. Nordic Science Investments spearheaded the funding round, with contributions from Specialist VC, Business Finland, and Harjavalta Ventures, among other investors. The Automated Image Measurement technology of the startup leverages images from ultrasound, computed tomography, and magnetic resonance imaging to analyse vascular imaging. This multimodal technology identifies abnormalities and quantifies changes over time in those at risk. It significantly reduces the time specialists spend on manual image measurements and documentation. As a result, clinicians can dedicate more time to patient care. AIATELLA is currently navigating the medical approval processes in several European and North American countries, including France, the US, and the UK. AIATELLA co-founder and CEO Jack Parker said: 'Our technology helps medical professionals analyse imaging much more efficiently, and at an earlier stage, so patients can get help before it's too late.' Initially applied to the aorta artery, AIATELLA's vision extends to encompass all blood vessels in the body with its technology. The startup noted that it is also developing a portable ultrasound-based screening technology for mass screening of individuals prior to the occurrence of symptoms. This approach aims to facilitate early detection of cardiovascular diseases, which are a major cause of mortality worldwide. The technology has already been employed in the UK and Finland at screening events, where it has helped identify potentially at-risk individuals. AIATELLA also aims to gather data on the presentation and progression of cardiovascular conditions across different sexes and ethnicities, as symptoms can vary widely among these different groups. "Finland's AIATELLA secures funds for AI cardiovascular imaging solutions" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Associated Press
35 minutes ago
- Associated Press
Digital Digest Unveils AI Insights Hub for Australian Businesses
SUNSHINE COAST, QUEENSLAND, AUSTRALIA / ACCESS Newswire / June 6, 2025 / Digital Digest, Australia's leading online publication for digital marketing insights, today announced the launch of its new AI Insights Hub. This is a dedicated resource designed to empower Australian businesses and professionals with expert, human-first guidance to navigate through the extensive range of AI tools becoming readily available to the market. The introduction of this comprehensive 'Australian Tailored' hub comes at a pivotal moment, as AI continues to fundamentally reshape every aspect digital marketing and how businesses alike can leverage AI platforms within business in Australia. Recent advancements, including Google's expanded AI Overviews and the integration of AI-powered tools across major platforms like Snapchat and YouTube, underscore the urgent need for clear, actionable intelligence and better understanding for business owners and professionals. The AI Hub will feature a collection of resources, including in-depth research reports on AI comparisions, trends specific to Australia, practical guides and case studies on how to best utilised AI across different industries. Along with this, upcoming exclusive interviews some of Australia's leading digital marketing professionals utilising AI and will provide exclusive insights into their tips and tricks for the best possible outcome. 'AI and Digital Marketing is undergoing an unprecedented transformation in 2025 and the majority driven by AI, and Australian businesses need a trusted partner to navigate these changes effectively,' stated Benjamin Paine, Founder at Digital Digest & Managing Director at Digital Nomads HQ. 'Our new AI Hub is a testament to our commitment to providing experienced insight and that we are dedicated to empowering marketers and business owners with the knowledge and tools necessary to leverage AI's immense potential.' The strategic importance of AI in digital marketing is further highlighted by its ability to enable faster decision-making, improve ROI, and enhance customer relationships through predictive analytics and intelligent automation. Digital Digest's new hub is poised to be an indispensable resource, offering the critical insights needed to capitalise on these opportunities. To explore the new AI Digital Marketing Insights Hub and access its comprehensive resources, please visit Media Contact Organization: Digital Nomads HQ PTY LTD Contact Person Name: Benjamin Paine Website: Email: [email protected] Contact Number: +1300633100 Address: 208/45 Brisbane Road Address 2: Mooloolaba City: Sunshine Coast State: Queensland Country: Australia SOURCE: Digital Nomads HQ PTY LTD press release


Forbes
39 minutes ago
- Forbes
Amid AI-Fueled Growth, AVGO Stock's Valuation Raises Concern
CANADA - 2025/01/06: In this photo illustration, the Broadcom company logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Broadcom (NASDAQ: AVGO) announced robust results for the second quarter of fiscal 2025 (ending in October), exceeding consensus estimates for both revenue and earnings. The company reported $15.0 billion in revenue, a 20% year-over-year increase, and adjusted earnings of $1.58 per share, up 44% year-over-year. These figures slightly surpassed analyst expectations of $14.97 billion and $1.57, respectively. This growth was primarily fueled by strong demand for Broadcom's AI semiconductor solutions and contributions from VMware. AI revenue alone surged by 46% year-over-year to over $4.4 billion in Q2, driven by robust demand for AI networking. Alongside impressive sales growth, the company's adjusted EBITDA margin significantly expanded by 700 basis points year-over-year, reaching 66.7% in Q2. Broadcom's outlook for Q3 also appears promising, with anticipated sales of $15.8 billion, slightly ahead of the $15.7 billion consensus. The company expects growth in AI semiconductor revenue to accelerate to $5.1 billion in Q3, with an adjusted EBITDA margin of at least 66%. Despite these solid results, AVGO stock saw a 4% decline in after-market trading on Thursday, June 5. This dip can partly be attributed to the stock's already high valuation. The question for investors is whether to buy AVGO stock at its current price of around $250. This is a tricky decision. While the stock appears attractive, its high valuation makes it particularly susceptible to adverse events, leading to potential volatility. Our analysis, which compares AVGO's current valuation to its recent operating performance and financial health, suggests minimal underlying concerns. Broadcom exhibits a very strong operating performance and financial condition across key parameters, including growth, profitability, financial stability, and downturn resilience. However, if you seek upside with less volatility than a single stock, consider the High-Quality portfolio, which has outperformed the S&P 500 and achieved returns greater than 91% since inception. Separately, see – Is Amazon Stock Still A Buy After Its Recent 25% Rally? Going by what you pay per dollar of sales or profit, AVGO stock looks very expensive compared to the broader market. Broadcom's Revenues have grown considerably over recent years. Broadcom's profit margins are much higher than most companies in the Trefis coverage universe. Broadcom's balance sheet looks strong. AVGO stock has fared worse than the benchmark S&P 500 index during some of the recent downturns. While investors have their fingers crossed for a soft landing by the U.S. economy, how bad can things get if there is another recession? Our dashboard How Low Can Stocks Go During A Market Crash captures how key stocks fared during and after the last six market crashes. In summary, Broadcom's performance across the parameters detailed above is as follows: - Growth: Extremely Strong - Profitability: Very Strong - Financial Stability: Strong - Downturn Resilience: Neutral - Overall: Strong Even though the stock has performed strongly in the parameters discussed, its extremely high valuation supports our conclusion that AVGO is a tricky stock to buy. We think investors would likely be better off waiting for a further dip before picking AVGO stock. Notably, the average analyst price estimate of $254 also suggests that the stock does not have significant room for growth. Of course, we could be wrong, and investors may continue to assign even higher valuation multiples to AVGO stock given its position in the AI boom. Sometimes, valuations take a back seat when investors get eager about the outlook. In fact, evaluating valuation contextually is just one of many approaches we take when constructing the Trefis High Quality (HQ) Portfolio. This portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last four years. This is because, as a group, HQ Portfolio stocks have provided better returns with less risk compared to the benchmark index, offering a less volatile investment experience, as evident in the HQ Portfolio's performance metrics.